Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.

Isomorphic Labs将利用这笔资金推动其世界领先的AI药物设计引擎，扩展其全球业务，并推进其候选药物管道的进展。

LONDON

伦敦

,

，

May 12, 2026

2026年5月12日

/PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $2.1 Billion in Series B funding. This latest round of investment will accelerate the company's evolution from pioneering novel AI models to applying them at scale.

/PRNewswire/ -- 人工智能优先的药物设计与开发公司Isomorphic Labs今日宣布，已完成21亿美元的B轮融资。此轮最新投资将加速公司从开创全新人工智能模型到大规模应用的转型进程。

The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs' global capital base.

本轮融资由Thrive Capital领投，现有支持者Alphabet和GV以及新投资者MGX、淡马锡、CapitalG和英国主权AI基金参与，大幅扩展了Isomorphic Labs的全球资本基础。

The new capital will be used for the continued development and deployment of Isomorphic Labs' AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic. Additionally, the funding will support our existing hiring targets by integrating world-class AI, engineering, drug design, and clinical talent across our sites; this global scale is crucial to Isomorphic Labs' long-term vision of applying AI-driven breakthroughs to the most complex biological and medical challenges and addressing the global burden of disease..

新资金将用于继续开发和部署同构实验室的AI药物设计引擎（IsoDDE），加速并扩大其治疗项目管道向临床推进。此外，这笔资金将通过在我们的各个站点整合世界级的AI、工程、药物设计和临床人才来支持我们现有的招聘目标；这种全球规模对于同构实验室的长期愿景至关重要，即将AI驱动的突破应用于最复杂的生物和医学挑战，并解决全球疾病负担。

This funding round serves as further validation of the progress of Isomorphic Labs' AI drug design capabilities and marks a pivotal moment for the company, demonstrating that its first-principles approach positions it to define the future of AI-driven drug design. By reimagining drug discovery as an integrated scientific and engineering discipline with proprietary AI and data at the core, Isomorphic Labs aims to deliver scientific breakthroughs with a level of precision and speed previously thought impossible..

本轮融资进一步验证了Isomorphic Labs在人工智能药物设计能力方面的进展，标志着公司迎来了一个关键转折点，表明其基于第一性原理的方法使其能够定义人工智能驱动药物设计的未来。通过将药物发现重新构想为一门以专有人工智能和数据为核心的集成科学与工程学科，Isomorphic Labs旨在以前所未有的精确度和速度实现科学突破。

'The application of AI in healthcare offers a profound opportunity. Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform,'

“人工智能在医疗保健领域的应用提供了一个深远的机会。Isomorphic Labs已经在利用人工智能加速药物发现方面取得了非凡的进展，我们对这一势头和技术平台的早期前景感到兴奋。”

said Ruth Porat, President and Chief Investment Officer Alphabet and Google.

阿尔phabet和谷歌的总裁兼首席投资官露丝·波拉特说。

'This trajectory is encouraging, and this funding will be used to accelerate the work and bring important interventions to market with greater speed.'

“这一发展轨迹令人鼓舞，这笔资金将用于加速工作进程，并以更快速度将重要干预措施推向市场。”

'This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development,' said

“本轮融资是一批来自不同领域的顶级国际投资者对我们以人工智能为先导的药物设计与开发方法的极大信任投票，”

Sir Demis Hassabis, Founder and CEO

德米斯·哈萨比斯爵士，创始人兼首席执行官

. 'Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.'

“既然我们已经证明了我们的方法在根本上是可行的，我们的重点是将我们的技术扩展到其全部潜力。这笔资金的注入使我们能够大规模构建我们的药物设计引擎，推动我们朝着解决所有疾病的目标前进。”

'This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programs by hitting key milestones and identifying viable candidates with unprecedented speed,' said

“这一里程碑的实现得益于我们的人工智能药物设计引擎的实力，它已经在我们的内部项目中证明了自己的价值，以空前的速度达成了关键里程碑并确定了可行的候选药物，”

Max Jaderberg, President of Isomorphic Labs

马克斯·贾德伯格，Isomorphic Labs总裁

. 'Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach.'

“我们的药物设计引擎有效，并且为我们提供了一种可重复的方法，可以为多种疾病设计新药，开创了以前无法企及的医学未来。”

'We are humbled to have the opportunity to continue to support Isomorphic's mission to solve all disease,'

“我们很荣幸有机会继续支持同构公司解决所有疾病的任务，

said Joshua Kushner, Founder and CEO of Thrive Capital.

约书亚·库什纳，Thrive Capital创始人兼首席执行官表示。

'Over the past year, our conviction in the team has only deepened as they've made significant progress in building a unified AI drug design engine to define a new age of drug discovery and design.'

“在过去的一年中，我们对团队的信心只增不减，因为他们已经在构建一个统一的 AI 药物设计引擎以定义药物发现和设计的新时代方面取得了重大进展。”

'The caliber of the team Isomorphic has assembled is unmatched, and they continue to validate our belief that this is the premier group at the intersection of AI and drug discovery,' said

“Isomorphic组建的团队实力无与伦比，他们不断验证了我们对其作为AI与药物发现领域顶尖团队的信心，”

Dr. Krishna Yeshwant, Managing Partner at GV.

GV管理合伙人Krishna Yeshwant博士。

'We have strong confidence in Isomorphic. We believe their approach can create important medicines that will be better understood earlier in the process, pushing the boundaries of what's been possible before.'

“我们对同构公司充满信心。我们相信他们的方法可以创造出在过程中更早被理解的重要药物，突破以往的可能界限。”

Technical Advancement and Strategic Impact

技术进步与战略影响

Isomorphic Labs has developed a number of proprietary breakthrough AI models that together form its unified AI drug design engine that works across multiple therapeutic areas and drug modalities. Isomorphic Labs recently

同构实验室开发了多个专有的突破性人工智能模型，这些模型共同构成了其统一的人工智能药物设计引擎，该引擎可跨多个治疗领域和药物模式工作。同构实验室最近

published

已发布

a subset of the powerful and expansive capabilities of IsoDDE, highlighting its predictive accuracy and introducing new capabilities which bridge the gap between structure prediction and real-world drug discovery. IsoDDE offers a scalable foundation for AI drug design, providing the predictive fidelity required to navigate novel biological systems with unprecedented accuracy..

IsoDDE强大而广泛功能的一个子集，展示了其预测准确性，并引入了弥合结构预测与现实药物发现之间差距的新能力。IsoDDE为人工智能药物设计提供了可扩展的基础，提供了以空前精度探索新颖生物系统所需的预测保真度。

Isomorphic Labs maintains a strong portfolio of strategic partnerships with industry leaders like Novartis, Lilly, and Johnson & Johnson. These collaborations serve as a significant validation of Isomorphic's AI-first approach and the tangible value it brings to the pharmaceutical industry.

Isomorphic Labs 与诺华、礼来和强生等行业领导者保持着强有力的战略合作伙伴关系。这些合作显著验证了 Isomorphic 以人工智能为先导的方法及其为制药行业带来的实际价值。

ABOUT ISOMORPHIC LABS

关于同构实验室

Isomorphic Labs was founded in 2021, to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs. Isomorphic Labs is led by CEO Sir Demis Hassabis and President Max Jaderberg. Isomorphic Labs has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities.

Isomorphic Labs 成立于2021年，旨在利用人工智能的力量变革药物发现，开启生物医学突破的新时代。Isomorphic Labs 由首席执行官戴密斯·哈萨比斯爵士和总裁马克斯·贾德伯格领导。Isomorphic Labs 构建了一个世界领先的AI药物设计引擎，包含能够跨多个治疗领域和药物模式工作的基础AI模型。

The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Isomorphic Labs is headquartered in London and has office locations in Cambridge, Massachusetts and Lausanne, Switzerland. Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs.

该公司不断在模型架构上创新，并开发尖端能力以推进药物设计。Isomorphic Labs 总部位于伦敦，在美国马萨诸塞州剑桥和瑞士洛桑设有办公地点。Isomorphic Labs 正通过合作项目和全资内部项目推动广泛且雄心勃勃的药物设计组合。

For more information, go to .

有关更多信息，请访问 。

www.isomorphiclabs.com

www.isomorphiclabs.com

and follow us on

关注我们

LinkedIn

领英

and

和

X

X

.

。

For Media Inquiries

媒体咨询请联系

[email protected]

电子邮件地址

SOURCE Isomorphic Labs

来源：同构实验室

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示